Halting Drivers of Chronic Kidney Disease ProgressionPremiere Date: Wednesday, October 6, 2021
This activity will offer CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, October 6, 2022
Note: Credit Is No Longer Available
|Dhiren K. Patel, PharmD, CDCES, BC-ADM (Moderator)
Adjunct Associate Professor of Pharmacy Practice
School of Pharmacy at Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacy Specialist
|Robert S. Busch, MD, FACE
Director of Clinical Research
Community Endocrine Group
Albany Med Faculty Practice
|Javier Morales, MD, FACP, FACE
Principal Clinical Trials Investigator
Advanced Internal Medicine Group, PC
East Hills, NY
Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Type 2 diabetes mellitus (T2DM) is a growing global health emergency that affects an estimated 29 million Americans and 463 million people worldwide, with that number projected to increase to 700 million by 2045. Approximately 40% of patients with T2DM develop chronic kidney disease (CKD), exposing patients to a 3-fold risk of cardiovascular death compared with those who do not develop CKD. CKD is an independent risk factor for cardiovascular disease (CVD), tripling the risk of heart attack or stroke and shortening the life expectancy of patients with T2DM by up to 16 years. CKD in T2DM is also associated with the following: end stage renal disease (ESRD), poorer health-related quality of life (HRQoL), significant disability, need for renal replacement therapy (dialysis), and increased renal and CV-associated mortality.
T2DM management guidelines have undergone a tremendous shift beyond A1C targets to a more comprehensive approach to reduce these complications. Pharmacists need up-to-date knowledge of current and emerging treatments that may delay CKD progression and reduce the risk of CV events.
At the end of this CE activity, participants should be able to:
- Recognize when a patient should undergo guideline-recommended screening with uACR and eGFR for early diagnosis of CKD in patients with T2DM
- Describe the pathophysiological features of CKD giving rise to renal, CV, and mortality risks in patients with CKD and T2DM, despite optimized management according to current standards of care (SOC).
- Assess new efficacy and safety data for current and emerging therapies for CKD in patients with T2DM.
Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
Physicians, pharmacists, PAs, nurse practitioners, and nurses
Specific CE Credit information is not available at this time. Please check again soon!
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Patel reports that he is on the speakers bureau for Abbott; Amarin Corporation; AstraZeneca; Bayer; Boehringer Ingelheim; Dexcom, Inc.; Lilly; Novo Nordisk; Xeris Pharmaceuticals, Inc.; and Zealand Pharma.
Dr. Busch reports that he receives research support from AstraZeneca; Bayer; Lilly; Novo Nordisk; and Pfizer Inc. He is on the speakers bureau for Amgen; Amylin Pharmaceuticals; AstraZeneca; Bayer; Boehringer Ingelheim; and Esperion Therapeutics.
Dr. Morales serves on the speakers bureau for Bayer; Boehringer Ingelheim; Lilly; and Novo Nordisk. He reports he consults for Bayer; Boehringer Ingelheim; Intarcia Therapeutics, Inc.; Lilly; and Novo Nordisk.
Jeffrey Helfand, DO, (peer reviewer) had no disclosures to report.
Julie Strickland, PharmD, (planning committee) has no disclosures to report.
Janan Sarwar, PharmD, (planning committee) has no disclosures to report.
Kathleen Blake, PhD, (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).